Snow-covered bodies of 2 men from Senegal found in New York woods near Canadian border
Two men from Senegal froze to death were found in the snow of a wooded area close to the Canadian border, New York state police said.
AstraZeneca said on Tuesday a late-stage trial failed to provide evidence that its COVID-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.
The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms.
The therapy, AZD7442, was 33 per cent effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.
The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.
Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants.
"While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442," AstraZeneca Executive Vice President Mene Pangalos said in a statement, referring to the polymerase chain reaction tests which diagnose COVID-19.
The company is banking on further studies to revive the product's fortunes. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention.
The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.
AZD7442 belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections.
Similar therapies developed by rivals Regeneron, Eli Lilly and GlaxoSmithKline with partner Vir have been approved by U.S. regulators for treating unhospitalised COVID patients.
Regeneron is also seeking U.S. authorisation for its therapy as a preventative treatment.
European regulators have recommended antibody treatments by GSK, Celltrion, Eli Lilly and Regeneron for used in early-stage patients who are at risk of progressing to severe COVID-19. The EU watchdog made the endorsement to support the use by member states ahead of an EU-wide marketing authorisation.
But the AstraZeneca results are a small blow for the drug industry as it tries to find more targeted alternatives to COVID-19 inoculations, particularly for people who may not be able to get vaccinated or those who may have an inadequate response to inoculations.
The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its COVID-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.
AstraZeneca also said on Tuesday it was in talks with the U.S. government on "next steps" regarding a US$205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza was contracted to produce AZD7442.
Shares in the company were largely unchanged on the London Stock Exchange.
The full results will be submitted for publication in a peer-reviewed medical journal, the company said.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Shounak Dasgupta, Kim Coghill and Emelia Sithole-Matarise)
Two men from Senegal froze to death were found in the snow of a wooded area close to the Canadian border, New York state police said.
Austin Hunter Turner died in 2017, on a night that his mother has rewound and replayed again and again, trying to make sense of what happened.
An historic downtown Toronto bar is closing its doors next week after nearly 200 years in business.
Niagara Region says it has declared a state of emergency 'out of an abundance of caution' as it prepares for an influx of visitors for next month’s total solar eclipse.
An Ontario man who built a garage on his property has been locked in a battle with his electricity provider for a year and half over a severed power line.
Neuroscientist Emma Duerden says social media can alter children's brains and have negative impacts on their mental health.
A breakthrough discovery made by doctors at the Montreal Children's Hospital about the causes of cerebral palsy is giving new hope to one West Island family.
Not getting enough sleep may cause you to feel five to 10 years older than you really are, according to two new studies.
An Edmonton broadcasting pioneer has passed away.
A Toronto restaurant introduced a surprising new rule that reduced the cost of a meal and raised the salaries of staff.
The spring allergy season has started early in many parts of Canada, with high levels of pollen in some cities already. Experts weigh in on which areas have it worse so far this season.
It was a typical Tuesday for Mabel Beharrell, 84, until she got the call that would turn her world upside down. Her teenaged grandson was in trouble and needed her help.
B.C. conservation officers recently seized a nine-foot-long Burmese python from a home in Chilliwack.
A New Brunswicker will go to bed Thursday night much richer than he was Wednesday after collecting on a winning lottery ticket he let sit on his bedroom dresser for nearly a year.
The Ontario government is introducing changes to auto-insurance, but some experts say the move is ill-advised.
Newfoundland’s unique version of the Pine Marten has grown out of its threatened designation.
A Toronto man is out $12,000 after falling victim to a deepfake cryptocurrency scam that appeared to involve Prime Minister Justin Trudeau.
It started small with a little pop tab collection to simply raise some money for charity and help someone — but it didn’t take long for word to get out that 10-year-old Jace Weber from Mildmay, Ont. was quickly building up a large supply of aluminum pop tabs.